Clinical trial NCT00640926: Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
Official title: A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of RX-1741 in the Treatment of Adult Patients With Mild to Moderate Severity of Community-Acquired Pneumonia (CAP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Community-Acquired Pneumonia (CAP)
Lead sponsor: Melinta Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2008-03-21
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).


Eligibility criteria: Inclusion Criteria:

* Adult patients with mild to moderate CAP.
* Adult men and women ≥18 years.
* Females must be post-menopausal for at least 1 year or surgically sterile (hysterectomy or tubal ligation).
* Sexually active males must use a barrier method of birth control during and for 30 days after the study. Their female partner should also use an additional reliable method of contraception during and for 30 days after the study.
* The patient must present with an acute respiratory illness (≤7 days duration) with which history and physical examination is consistent with a diagnosis of CAP.

Patients requiring immediate study drug therapy before serology or culture results are known may be entered with a presumptive diagnosis of CAP based on:

A chest radiograph at baseline, which shows a new infiltrate(s) consistent with pneumonia as interpreted by the radiologist or the investigator and subsequently confirmed by the radiologist.

AND at least 2 of the following signs and symptoms:

New or increased cough. Purulent sputum or change in sputum character. Auscultatory findings consistent with pneumonia. New onset or progressive dyspnea or tachypnea. Fever \>38ºC oral or \>38.5ºC tympanic. White blood cell (WBC) count greater than 10,000 cells/mm3 or \>15% immature neutrophils (bands), regardless of total peripheral WBC count, or less than 4,500 cells/mm3.

Patient must be able to swallow large capsules intact.

A written, voluntarily signed informed consent must be obtained from the patient prior to the initiation of any study-related procedures.

Exclusion Criteria:

* Hypersensitivity to linezolid.
* Patients are excluded if they have taken oral or parenteral antibiotics as follows:

long-acting penicillin within 28 days of enrollment azithromycin, ceftriaxone, or telithromycin within 14 days prior to enrollment any other antibiotics for \>24 hours within 3 days of enrollment

* Require parenteral antibiotics for the treatment for CAP.
* Patient should not have been hospitalized or resided in a long-term facility for at least 14 days before the onset of symptoms.
* Evidence of other pulmonary disease that precluded evaluation of therapeutic response. Patients with known bronchial obstruction or a history of postobstructive pneumonia. (This does not exclude patients who have chronic obstructive pulmonary disease).
* Experienced a recent clinically significant coagulopathy.
* History of cystic fibrosis, active tuberculosis, meningitis, endocarditis, or osteomyelitis.
* Immunocompromised patients including, but not limited to patients with a CD4+ cell count of \<350 cells/mm3 secondary to human immunodeficiency virus (HIV) infection, neutropenic patients with granulocytes \<1000/mm3 or immunosuppression secondary to drugs such as corticosteroid therapy (\>10 mg/day of prednisone or equivalent for at least the past 3 months), splenectomized patients or patients with known hyposplenia or asplenia.
* Patients who have severe liver disease.
* Treatment with an investigational drug within 4 weeks prior to study drug administration.
* Any underlying condition or disease state that would interfere with the completion of the study procedures and evaluation of the absorption of study drug.
* Patients with bronchiectasis and a history of recent respiratory infection caused by Pseudomonas aeruginosa.
* Any infection which requires the use of a concomitant antimicrobial agent, in addition to study drug.
* Patients taking serotonergic agents, selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors (MAOIs).

Primary outcomes:
measure: Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC)
timeFrame: Study days 14-38
Secondary outcomes:
Other outcomes:
measure: Per Patient Microbiological Response of Eradicated in the Microbiologically Evaluable (ME) Population at Test of Cure (TOC)
timeFrame: Study Days 14-38
Locations:
city: San Diego
country: United States
facility: eStudySite
state: California
city: Sylmar
country: United States
facility: Olive View- UCLA Center, Dept. Emergency Medicine
state: California
city: Detroit
country: United States
facility: Wayne State University School of Medicine/Detroit Receiving Hospital
state: Michigan
city: Keego Harbor
country: United States
facility: Arnold Markowitz, MD
state: Michigan
city: Butte
country: United States
facility: Mercury Street Medical Group, LLC
state: Montana
city: Belvidere
country: United States
facility: Dr. John Bernard
state: New Jersey
city: Cherry Hill
country: United States
facility: University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine (UMDNJ-SOM)
state: New Jersey
city: Warminster
country: United States
facility: Warminster Medical Associates, P.C.
state: Pennsylvania
city: Burnaby
country: Canada
facility: Ronald Collette, MD
state: British Columbia
city: Kelowna
country: Canada
facility: The Medical Arts Health Research Group
state: British Columbia
city: North Vancouver
country: Canada
facility: Westview Research
state: British Columbia
city: Penticton
country: Canada
facility: The Medical Arts Health Research Group
state: British Columbia
city: Bathurst
country: Canada
facility: Maritime Research Center
state: New Brunswick
city: Hawkesbury
country: Canada
facility: Source Unique Research
state: Ontario
city: London
country: Canada
facility: Gordon Schacter, MD
state: Ontario
city: London
country: Canada
facility: London East Medical Centre
state: Ontario
city: Newmarket
country: Canada
facility: SKDS Research Inc.
state: Ontario
city: Ottawa
country: Canada
facility: University of Ottawa Health Services
state: Ontario
city: Sarnia
country: Canada
facility: London Road Diagnostic Clinic and Medical Centre
state: Ontario
city: Montague
country: Canada
facility: Kings County Medical Centre
state: Prince Edward Island
city: Drummondville
country: Canada
facility: Rhodin Recherche Clinique
state: Quebec
city: Montreal
country: Canada
facility: Centre Medical Acadie
state: Quebec
city: Moscow
country: Russian Federation
facility: Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirsky
city: Moscow
country: Russian Federation
facility: Moscow State Medico-Stomatological University
city: Moscow
country: Russian Federation
facility: State Healthcare Institution "City Clinical Hospital # 29"
city: Moscow
country: Russian Federation
facility: State Healthcare Institution Moscow
city: St. Petersburg
country: Russian Federation
facility: City Hospital # 31
city: St. Petersburg
country: Russian Federation
facility: St. Petersburg City Hospital # 26
city: St. Petersburg
country: Russian Federation
facility: St. Petersburg Pavlov State Medical University
city: St. Petersburg
country: Russian Federation
facility: St. Petersburg Scientific-Research Institute of Pulmonology at State Medical University named after Academician I.P. Pavlov
Study officials:
References: